Gsk Share Discussion Threads

[alphorn] 28/1/2019 11:24

There is always a major difference between outsourcing a service and being the owner of the IP with its returns. In the middle there are the generics.

[wbecki] 28/1/2019 11:21

Hardly the end of the world Essential.

"Small drug companies grow as big pharma outsources"



More important imo.

Swings and roundabouts.

Just as there have been winners(and losers) from 41 years of EU membership, so there will be winners(and losers) when we Leave.

[alphorn] 28/1/2019 11:01

TM - 'material' is an accounting term as you probably know. That would be a very large impact; this ITO does not fall into that category.

[tradermichael] 28/1/2019 10:59

Not according to the board!

[alphorn] 28/1/2019 10:41

"not have a material impact"

Can still be pretty big!

[tradermichael] 28/1/2019 10:22

Let's have no more of this Project Fear, eh?

Our (GSK) approach to Brexit
We have evaluated the impact of Brexit on our business operations, including our supply chain and quality oversight. Our priority is to maintain continuity of GSK’s supply of medicines, vaccines and health products to our patients and consumers in the UK and the EU.
Uncertainty remains about the future relationship between the UK and the EU. As a result, we have agreed a risk-based approach to mitigation across the organisation. Implementation of our contingency plan has been underway since January 2018, with an immediate focus on our supply chains. This includes expanding our ability in the EU and the UK to conduct re-testing and certification of medicines; transferring Marketing Authorisations registered in the UK to an EU entity; updating packaging and packaging leaflets; amending manufacturing and importation licences, and securing additional warehousing.
We currently anticipate that the cost to implement these and other necessary changes could be up to £70 million over the next two to three years, with subsequent ongoing additional costs of approximately £50 million per year, including additional customs duties and transaction or administration costs. These charges represent our estimates of the impact of Brexit based on the information currently available. As more information on the changes to our business that will be required after Brexit becomes available, the assumptions underlying these estimates could change, with consequent adjustments, either up or down, to the additional costs we expect to incur. We will continue to adjust our plans and their expected financial impact as negotiations and regulations develop.
Delivering these necessary but complex changes by March 2019 will be ambitious and potentially disruptive in the short term and we support efforts to secure a status quo transition period to minimise disruption.

Over the longer term, we continue to believe that Brexit will not have a material impact on our business.

[dr biotech] 28/1/2019 09:57

Will be interesting to see what they say about brexit. I work a lot in labs and last week I met the first person who admitted they voted out. He’s since changed his mind and would now vote remain. Labs have a lot of well educated Europeans in them - they are going to get clobbered when free movement ends. Plus the EMA relocating to Amsterdam plus customs etc. We’ve relocated our warehouse to Karlsruhe. Only 4 people, but customers need things next day and Europe’s more important.

[tradermichael] 28/1/2019 09:53

£1 = $1.32, not so good ….. ;0(

[tradermichael] 28/1/2019 09:12

Results a week on Wednesday (6 February) to bear in mind …… ;0)

[ny boy] 28/1/2019 08:50

Usual kiss of death buy rating from HSBC lol

Looking to add on any further weakness before ex div 21 Feb

[montyhedge] 27/1/2019 14:30

The new wonder vaccination for Shingles so successful, now a shortage, that's why they fallen.

[bolador] 27/1/2019 13:24

abdulla,

strong sterling versus dollar last week makes for weak GSK and is bear point also for VOD.

[essentialinvestor] 27/1/2019 12:42

If we stumble in to a no deal, the hit to GBP makes GSK
significantly more attractive on a short term basis. I suppose you
could view it as a no deal hedge in that respect.

Otherwise my take is lower levels may well be available to add.

[tradermichael] 27/1/2019 12:36

GlaxoSmithKline (LON:GSK) has been given a GBX 1,820 price objective by equities researchers at HSBC in a report released on Friday. The brokerage presently has a “buy” rating on the stock. HSBC’s price target points to a potential upside of 26.35% from the company’s previous close.

[solomon] 26/1/2019 16:25

Another story about the demand for Shingrix:

[wbecki] 26/1/2019 11:26

GlaxoSmithKline: Watching Dividend Trends Closely



Interesting snippet.

[badtime] 25/1/2019 18:56

So it's not if but now when ...blimey only 24 hours and you've changed your mind already :)

[abdullla] 25/1/2019 17:22

GSK and Vodafone dropping together like pals .

[essentialinvestor] 25/1/2019 13:08

Unless I've missed it, not seen a great deal of positive pipeline newsflow
of late?.

The chair leaving with arguably a job half done.

[alphorn] 25/1/2019 12:52

TM - it highlights the inherent risk in this sector. Without it there would not be the potential advances in health/wealth. None of these investments are sure winners; that is the name of the game.

[tradermichael] 25/1/2019 12:49

The acquisition of Tesaro(for GBP4.0 billion), which was announced on 3 December 2018, "significantly strengthens GSK's pharmaceutical business, accelerating the build of GSK's pipeline and commercial capability in oncology."


Let's assume that the experts at GSK already know a lot more about the opportunity ahead with this acquisition. Its a massive stake.

[wbecki] 25/1/2019 11:44

HSBC SEES GLAXOSMITHKLINE AS ONE OF THE BEST GLOBAL STOCK IDEAS

[tradermichael] 25/1/2019 11:08

Except that, without humans as hosts, most microbes mentioned would not survive! Its not in their interest to develop total immunity and to wipe us out!